Bio-Rad Laboratories (BIO-B) Share-based Compensation (2009 - 2025)

Bio-Rad Laboratories (BIO-B) has 17 years of Share-based Compensation data on file, last reported at $15.9 million in Q4 2025.

• Share-based Compensation for Q4 2025 came in at $15.9 million, down 3.05% year-over-year; the trailing twelve-month figure through Dec 2025 was $62.8 million (down 2.03% YoY), and the FY2025 annual result was $58.0 million, down 6.9% from the prior year.
• Share-based Compensation advanced to $15.9 million in Q4 2025 per BIO-B's latest filing, from $14.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $18.1 million in Q4 2022 and troughed at $11.4 million in Q2 2021.
• A 5-year average of $14.8 million and a median of $15.3 million in 2021 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2021 and 2023: Share-based Compensation rose 29.55% in 2021, then decreased 10.5% in 2023.
• A 5-year view of Share-based Compensation shows it stood at $15.0 million in 2021, then increased by 20.67% to $18.1 million in 2022, then decreased by 10.5% to $16.2 million in 2023, then climbed by 1.23% to $16.4 million in 2024, then fell by 3.05% to $15.9 million in 2025.
• Business Quant data shows BIO-B's Share-based Compensation at $15.9 million in Q4 2025, $14.9 million in Q3 2025, and $16.4 million in Q4 2024.